PR - Virasoft - Digital Pathology Workflow & AI Solutions

Decision Support & AI

PR

Progesterone receptor (PR) is a nuclear receptor activated by the hormone progesterone and stimulates the growth of tumor cells. It is routinely evaluated by immunohistochemical method in invasive breast cancers.

PR has a nuclear staining pattern that shows weak, medium and dark staining intensity in microscopic evaluation. In the assessment of PR positivity, the ratio of the positive stained tumor cells to all tumor cells is calculated [1].

Back to Other Samples

Keywords

Progesterone Receptor, Hormone Therapy, Image Analysis

Methods

The techniques of nuclear classification algorithm is used to detect the nuclei in morphological form and size and classify them as positive or negative according to pixel colorization and intensity. Also, tile extraction, color deconvolution, morphological filters, threshold value method,and cell segmentation algorithms are used to develop PR analysis.

The analysis algorithm contains H-DAB colour deconvolution method. To detect negative nuclei H channel, and to detect and classify brown nuclei DAB channel are used. The positive nuclei are classified into three groups according to given threshold values by the user before running the analysis.

Quantitative output variables

H-Score
Dark Brown Nuclei Number
Medium Brown Nuclei Number
Light Brown Nuclei Number
Blue Nuclei Number
Stroma Nuclei Number
PR Positivity

Workflows

View the ER whole slide digital image with ViraPath.
Outline tumor either manually or automatically using Virapath Tissue Segmentation algorithm.
Select ER analysis and calibrate the parameters.
Run the analysis.

References

[1] Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., ... & Hicks, D. G. (2010). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Archives of pathology & laboratory medicine, 134(7), e48-e72.